Skip to main content

Table 2 Univariate analysis of prognostic factors associated with survival and recurrence

From: Glutamine deficiency promotes recurrence and metastasis in colorectal cancer through enhancing epithelial–mesenchymal transition

Variables

OS

DFS

Hazard ratio (95% CI)

P value

Hazard ratio (95% CI)

P value

Age (year)

 ≥ 65 versus < 65

1.513 (0.823, 2.782)

0.183

0.910 (0.516, 1.602)

0.743

Gender

 Male versus female

0.870 (0.462, 1.637)

0.666

1.000 (0.563, 1.776)

0.999

BMI

0.030*

 

0.833

 18.5–23.9 vs. < 18.5

0.374 (0.160, 0.876)

0.024*

0.710 (0.272, 1.856)

0.485

 24–26.9 vs. < 18.5

0.260 (0.093, 0.724)

0.010*

0.757 (0.269, 2.132)

0.598

 ≥ 27 vs. < 18.5

0.191 (0.049, 0.742)

0.017*

0.563 (0.162, 1.948)

0.364

Tumor size(cm)

 ≥ 5 versus < 5

0.624 (0.328, 1.187)

0.151

1.260 (0.708, 2.242)

0.433

Tumor location

 Colon versus rectum

1.840 (0.987, 3.432)

0.055

1.785 (1.003, 3.179)

0.049*

Tumor differentiation

 Well and moderate versus poor

0.244 (0.131, 0.454)

0.013*

0.337 (0.186, 0.611)

0.000*

Depth of invasion

0.002*

 

0.003*

 T3 versus Tis–T2

1.984 (0.693, 5.681)

0.202

5.902 (1.419, 24.556)

0.015*

 T4 versus Tis–T2

5.706 (1.815, 17.946)

0.003*

12.019 (2.656, 54.385)

0.001*

Lymph node metastasis

 Yes versus no

2.021 (1.074, 3.805)

0.029*

3.381 (1.816, 6.293)

0.000*

Venous permeation

 Yes versus no

2.544 (1.352, 4.786)

0.004*

3.038 (1.680, 5.497)

0.000*

Perineural invasion

 Yes versus no

2.572 (1.377, 4.805)

0.003*

2.565 (1431, 4.598)

0.002*

Adjuvant therapy

 Yes versus no

0.285 (0.147, 0.552)

0.000*

0.569 (0.323, 1.004)

0.052

Serum glutamine

 ≤ 392.83versus > 392.83

1.998 (1.090, 3.663)

0.025*

2.464 (1.402, 4.330)

0.002

  1. OS overall survival, DFS disease-free survival, 95% CI 95% confidence interval
  2. *Statistically significant